Table 3.
Cell Line/Cancer Type | Compound | Effect (Cell Viability Assay) |
Reference |
---|---|---|---|
AZ521 (Gastric) |
Steviol, isosteviol derivatives |
Increased cytotoxicity (MTT Assay) |
[44] |
HGC-27 (Gastric) |
Steviol | Increased cytotoxicity, G1 arrest (MTT Assay) |
[43] |
MKN-45 (Gastric) |
Steviol | Increased cytotoxicity, G1 arrest, apoptosis, regulation of miR-1268b and miR-23c (MTT Assay) |
[43] |
MGC-803 (Gastric) |
Steviol | Increased cytotoxicity, G2 arrest (MTT Assay) |
[43] |
NUGC-3 (Gastric) |
Isosteviol | Increased cytotoxicity (MTT Assay) |
[45] |
Caco-2 (Colorectal) |
Aqueous extract | Decreased cell viability (MTT Assay) |
[37] |
Steviol | Increased cytotoxicity, G1 arrest (MTT Assay) |
[43] | |
HCT116 (Colorectal) |
Isosteviol Triazole Conjugates | Increased cytotoxicity (MTT Assay) |
[28] |
Stevioside, ethanolic extract | Increased cytotoxicity (MTT Assay) |
[46] | |
Steviol | Cell proliferation inhibition, G1 arrest, apoptosis regulation of miR-203a-3p and miR-6088 (MTT Assay) |
[43] | |
HCT-8 (Colorectal) |
Steviol | Cell proliferation inhibition, G2 arrest (MTT Assay) |
[43] |
Hep3B (Hepatocarcinoma) |
Steviolbioside | Cell proliferation inhibition (MTT Assay) |
[27] |
HepG2 (Hepatocarcinoma) |
Aqueous extract, stevioside, RebA |
No cytotoxicity (LDH and BRDU assays) |
[10] |
Commercialized stevia, Stevioside | Increased cytotoxicity, cholesterol internalization (MTT Assay) |
[47] | |
Ammonium derivatives of steviol and isosteviol | Increased cytotoxicity (Multifunctional Cytell Cell Imaging system) |
[24] | |
ASPC-1 (Pancreatic) |
Isosteviol Triazole Conjugates | Increased cytotoxicity (MTT Assay) |
[28] |
BxPC-3 (Pancreatic) |
Steviolbioside | Cell proliferation inhibition (MTT Assay) |
[27] |
MiaPaCa-2 (Pancreatic) |
Stevioside, ethanolic extract | Increased cytotoxicity (MTT Assay) |
[46] |